The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China | |
Xing, Puyuan; Zhu, Yixiang; Shan, Ling; Chen, Sipeng; Hao, Xuezhi; Li, Junling | |
刊名 | ONCOTARGET |
2017 | |
卷号 | 8期号:50 |
关键词 | advanced non-small cell lung cancer (NSCLC) multiple treatments taxane nanoparticle albumin bound paclitaxel (Nab-PTX) secreted protein acidic and rich in cysteine (SPARC) |
ISSN号 | 1949-2553 |
URL标识 | 查看原文 |
语种 | 英语 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/3612441 |
专题 | 复旦大学上海医学院 |
推荐引用方式 GB/T 7714 | Xing, Puyuan,Zhu, Yixiang,Shan, Ling,et al. The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China[J]. ONCOTARGET,2017,8(50). |
APA | Xing, Puyuan,Zhu, Yixiang,Shan, Ling,Chen, Sipeng,Hao, Xuezhi,&Li, Junling.(2017).The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China.ONCOTARGET,8(50). |
MLA | Xing, Puyuan,et al."The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China".ONCOTARGET 8.50(2017). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论